More "Good Days": Eptinezumab's Impact on Chronic Migraine

Research Summary

A recent study published in The Journal of Headache and Pain explored the relationship between good days per month and the impact of migraines in individuals with chronic migraine using data from the REVIEW study of eptinezumab. This post hoc analysis found that increases in good days per month were associated with a significant decrease in migraine-related disease impact. The findings suggest that treatments like eptinezumab can potentially improve the quality of life for those suffering from chronic migraine by increasing the number of days they experience without debilitating symptoms. Such insights could guide future research and treatment strategies for chronic migraine sufferers.

Study Details

📄 Title: Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine.

👥 Research Team: Khan FA et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Nov 26

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.